Detection and genotyping of CMV and HPV in tumors and fallopian tubes from epithelial ovarian cancer patients

Edyta Paradowska1*, Agnieszka Jabłońska1, Mirosława Studzińska1, Miłosz Wilczyński2 & Jacek R. Wilczyński3

Viral and bacterial infections are detected in epithelial ovarian cancer (EOC) tissues. Since the fallopian tubes are often affected by pelvic inflammatory disease (PID) and the majority of serous EOCs appear to originate from dysplastic lesions in the distal tube, it is relevant to consider the potential role that infectious agents may play in ovarian carcinogenesis. We sought to analyze the prevalence of human papillomavirus (HPV) and cytomegalovirus (CMV) in EOC tissue and fallopian tube specimens obtained at tumor resection. Ovarian cancer and fallopian tube tissue samples obtained from patients with EOC were analyzed by both qualitative and quantitative PCR to detect and quantify viral DNA. The presence of CMV and HPV DNA was detected in 70% and 74% cancerous ovarian tissues, respectively, and was significantly higher in EOC than in benign tumor cases ($P \leq 0.01$). CMV or HPV infection was observed also in the fallopian tube samples. Infection with HPV16 was determined in 70% of EOC cases. Almost two thirds of EOC patients demonstrated coinfection with CMV and HPV in the pathological samples. The results revealed that the presence of CMV and HPV in EOC samples is common. CMV and HPV infections can be potential risks for EOC development.

Ovarian cancer is the leading cause of cancer-related deaths in women, accounting for almost 300,000 new cancer cases, and 185,000 deaths in 2018 worldwide1. It has nonspecific symptoms, causing more than 60% of cases to be diagnosed at the advanced stage2. Ovarian cancer is a highly fatal disease, with a global 5-year age-standardized survival rate of 30–40% in women at advanced stages of diagnosis3,4. Approximately 90% of all ovarian cancers have epithelial origins and these cancers are more invasive5. Ovarian cancer is a heterogeneous disease that can be divided into three most common types: epithelial ovarian cancer (EOC), germ cell tumors, and sex cord-stromal tumors. The most common EOC histologic subtypes are serous, mucinous, endometrioid, clear-cell, or any combination of these subtypes6. The various histotypes are associated with distinct molecular alterations with different etiology, epidemiology, treatment, and prognosis. High-grade serous ovarian carcinoma (HGSOC) is the most aggressive and common subtype of EOC, representing approximately 75% of EOC cases7. EOCs originate from the ovarian surface epithelium and from serous tubal intraepithelial carcinomas (STICs) from the fallopian tube epithelium8-10. The fimbriae of the fallopian tube, which are in close proximity to the ovarian surface, have been suggested as the primary site of HGSOC origin11. The presence of lesions in the fallopian tube that have cytological features similar to those observed in HGSOCs is designated as STIC11. STICs harbor clonal mutations in the TP53 gene encoding the tumor suppressor p53, indicating that these molecular alterations are an early event in the oncogenesis of HGSOCs14,15. A large and growing body of literature supports a theory that STIC is a precursor of HGSOC involving uterine adnexa and peritoneum16.

More than one-fifth of ovarian carcinoma appears to be associated with inherited risk, including mutations, e.g., mutations in the BRCA1/2 and TP53 genes17,18. Among other factors, such as hereditary, environment, and lifestyle, chronic inflammation seems to be an important risk factor for EOC development. Epithelial cells are exposed to increased levels of inflammatory mediators including pro-inflammatory cytokines, chemokines and...
hormones that induce DNA damage via oxidative stress and contribute to increased cell division, genetic and epigenetic changes. The main causes of inflammation in the ovaries and fallopian tubes are ovulation, infection, and endometriosis. The predominant hypothesis on ovarian carcinogenesis suggests that incessant ovulation, ovarian rupture and inflammation cause a pro-oxidative microenvironment and mutagenic DNA damage. Pelvic inflammatory disease (PID), an infection of the female reproductive organs, also results in DNA damage and a pro-inflammatory response. The role of environmental factors such as bacterial (e.g., Chlamydia trachomatis, Mycoplasma genitalium) and viral infections is still under investigation. Recently, it has been shown that C. trachomatis DNA is highly expressed in tubal serous cancer compared with high-grade serous ovarian cancer. Some reports confirmed the presence of human papilloma virus (HPV) in malignant ovarian cancer, while others did not. High-risk HPV (HR-HPV) types 16 and 18 were the predominant genotypes associated with advanced stages. However, the low-risk HPV (LR-HPV) type 6 was also detected. The HR-HPV E6 and E7 oncoproteins can inactivate the tumor suppressors' p53 and Rb, respectively. Evidence of cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) infection in ovarian cancer tissues was also detected. These widespread herpesviruses can establish life-long infections and contain oncoproteins promoting malignant transformation and metastasis. CMV can spread to the upper genital tract and persistent infection is usually asymptomatic. The oncomodulatory properties of CMV may play an important role in ovarian carcinogenesis and disease progression.

To elucidate the potential role of viruses in ovarian carcinogenesis, the prevalence of HPV types and herpesviruses in EOC and fallopian tube tissue samples was determined. Variation in the UL55 and the US28 genes was determined in all patients with active CMV infection.

**Results**

**Study population.** The tissue material from patients with EOC consisted of 20 HGSOCs, four adenocarcinomas (mucinous or clear-cell), and other cell neoplasms. According to the FIGO stage distribution, two patients had stage I, one patient had stage II, 20 had stage III, and 4 had stage IV. In addition, four metastatic tumors and eight benign tumors as control group were included in the study. The average age at which the EOC patients were examined was 63.3 years (median age 66.0 years; range 34–85 years), while in the control group, it was 55.0 years (median age 53.5 years; range 37–88 years). The demographic and clinical characteristics of the patients are summarized in Table 1.

**Detection of herpesvirus infection.** DNA isolated from blood, primary cancer cells, tumors, and fallopian tube samples was examined by nested PCR and quantitative real-time PCR (qRT-PCR) assays for the

### Table 1. Patient characteristics

| Patient characteristics | Epithelial ovarian cancer (n = 27) | Metastatic ovarian cancer (n = 4) | Benign tumors (n = 8) |
|--------------------------|----------------------------------|----------------------------------|----------------------|
| Median age, years (range) | 66.0 (34–85)                    | 53.5 (37–88)                     | 53.5 (37–88)         |
| Tumor histology          |                                  |                                  |                      |
| HGSOCa                   | 20                               | 1                                | 5                    |
| Other types              | 7                                | 1                                | 0                    |
| BOTb                     | 2                                |                                  | 1                    |
| Mucinous adenocarcinoma  | 2                                |                                  | 1                    |
| Clearcell adenocarcinoma | 2                                |                                  | 1                    |
| Undifferentiated carcinoma| 1                               |                                  | 1                    |
| FIGO stagec              |                                  |                                  |                      |
| I                        | 2 (7.4%)                         |                                  | 1 (7.7%)             |
| II                       | 1 (3.7%)                         |                                  | 1 (7.7%)             |
| III                      | 20 (74.1%)                       |                                  | 20 (74.1%)           |
| IV                       | 4 (14.8%)                        |                                  | 4 (14.8%)            |

aHGSOC – high-grade serous ovarian cancer; bBOT – serous border-line ovarian tumor; cThe International Federation of Gynecology and Obstetrics (FIGO) clinical stage.
detection of CMV, EBV, and HSV-1. CMV infection was confirmed on the basis of CMV DNA detection (Fig. 1) and the results of serological assays. The CMV viremia was confirmed in 16/27 (59.3%) patients with EOC, all patients with metastatic tumors, and in 3/8 (37.5%) individuals with benign tumors. CMV DNA was detected in 19/27 (70.4%) of ovarian cancer samples and in all tissue samples obtained from patients with metastatic cancer. In the control patients with benign cancers, all ovarian samples were negative. The frequency of CMV DNA detection was significantly higher in EOC than in benign tumor cases (odds ratio, OR 39.00; 95% confidence interval, CI: 2.01–756.00; \( P = 0.0005 \)).

In addition, CMV DNA was detected in three samples of the fallopian tube derived from patients with EOC and in one sample obtained from a patient with metastatic adenocarcinoma. Among the 20 patients with HGSOC, CMV DNA was found in 14 (70.0%) of ovarian cancer specimens. Sequence analysis of the PCR products revealed that 18/19 (94.7%) of CMV-positive patients with EOC were infected with the CMV gB2 (UL55) genotype and one with the gB5 genotype. In all cases, the US28 A2 genotype of CMV was found. These CMV genotypes occurred also in patients with metastatic cancer.

A real-time PCR assay was used to quantify CMV DNA levels in blood and tissue samples. CMV DNA was detected in two of the 27 EOC samples (7.4%) using the genesig Standard Kit. The mean CMV DNA concentration

| Virus         | EOC (n) | EOC (n) | \( P \)-value EOC/Metastasis | \( P \)-value EOC/Benign tumors |
|---------------|---------|---------|-----------------------------|-------------------------------|
| CMV           | 19/27 (70.4) | 0/8 (0) | 0.0005*                    | 4/4 (100)                    | 0.550 |
| HPV6          | 2/27 (7.4)   | 0/8 (0) | 1.000                      | 0/4 (0)                       | 1.000 |
| HPV16         | 19/27 (70.4) | 2/8 (25.0) | 0.039*                    | 4/4 (100)                    | 0.550 |
| HPV18         | 0/27 (0)     | 0/8 (0) | 1.000                      | 0/4 (0)                       | 1.000 |
| HPV45         | 1/27 (3.7)   | 0/8 (0) | 1.000                      | 0/4 (0)                       | 1.000 |
| CMV/HPV6      | 2/27 (7.4)   | 0/8 (0) | 1.000                      | 0/4 (0)                       | 1.000 |
| CMV/HPV16     | 16/27 (59.3) | 9/8 (0) | 0.004*                    | 4/4 (100)                    | 0.269 |
| CMV/HPV45     | 1/27 (3.7)   | 0/8 (0) | 1.000                      | 0/4 (0)                       | 1.000 |
| EBV           | 0/24 (0)     | 0/8 (0) | 1.000                      | 0/4 (0)                       | 1.000 |
| HSV-1         | 0/24 (0)     | 0/8 (0) | 1.000                      | 0/4 (0)                       | 1.000 |

* The significance \( P \)-value between prevalence in EOC and benign tumor samples; \( ^* \) the significance \( P \)-value between prevalence in EOC and metastatic samples; \( \odds \text{ ratio (OR)} 39.00, 95\% \text{ confidence interval (CI)} 2.01–756.00; \( \odds \text{ ratio (OR)} 7.12, 95\% \text{ CI} 1.18–43.16; \( \odds \text{ ratio (OR)} 24.39, 95\% \text{ CI} 1.28–466.30.
in infected tissues was $3.59 \times 10^2$ copies/25 mg; range $3.13 \times 10^2$–$4.35 \times 10^2$ copies (Fig. 2A). Serum samples collected from patients with EOC were CMV- IgM and IgG positive in 61.5% and 92.3% cases, respectively. None of the tumor and blood samples were positive for EBV or HSV-1 DNA based on qRT-PCR and PCR (EBV) analysis.

**Detection of HPV types.** We examined the prevalence of HPV genotypes in tumor tissue samples by polymerase chain reaction. HPV genotypes determined by PCR were sequenced, and no discrepancies were found. HPV DNA was detected in approximately 74.1% (20/27) of EOC tissue samples (Table 2). The most common HPV types found in EOC samples were HPV16 (19/27, 70.4%), followed by HPV6 and HPV45. Two patients were positive for HPV6 (cancer or fallopian tube samples), whereas ovarian sample from one patient was infected with HPV45. In addition, HPV16 DNA in all cases of metastatic tumors and in 25.0% (2/8) benign tumors was detected. The HPV16 DNA was detected more frequently in tissues from patients with EOC compared to benign tumors (OR 7.12; 95% CI: 1.18–43.16; $P = 0.039$). The significance of these results must be handled with caution due to small sample size in both patient groups. In addition, HPV16 DNA in the blood samples from 7/27 (25.9%) patients with EOC and 2/4 (50.0%) metastatic tumors has been detected. HPV infection was observed in the fallopian tube samples of five patients with EOC (HPV16 in four cases and HPV6 in one case) and three patients with metastasis (HPV16). Analysis of specimens obtained from patients with HGSOC showed that HPV16 DNA was detected in 14/20 (70.0%) EOC samples.

Using qRT-PCR assays, high-risk HPV16 was detected in two samples of EOC (2/27, 7.4%). The HPV16 DNA concentration was low ($1.34 \times 10^2$ copies and $2.33 \times 10^2$ copies/25 mg; Fig. 2B). None of the samples analyzed for HPV subtypes 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 tested were positive.
Coinfection with both CMV and HPV was observed in samples obtained from seventeen patients with EOC (63.0%), including 16 cases with CMV and HPV16 infection (one case with CMV, HPV6 and HPV16), and one case with CMV, HPV6 and HPV45 infection (Table 2). Moreover, the frequency of CMV and HPV16 coinfection was significantly higher in EOC than in benign tumor cases ($P = 0.004$; Fisher’s exact test). Univariate analysis revealed that the odds of being coinfected were 24 times greater for cases with EOC than those with benign tumor (OR 24.39; 95% CI 1.28–466.30).

**Discussion**

In this study, the presence of CMV and/or HPV was detected both in cancer and fallopian tube DNA isolated from patients with EOC. Among the examined patients, especially those with HGSOC, CMV and HPV DNAemia was common and was detected in more than two thirds of patients. Furthermore, more than half of the patients with EOC were coinfected with both CMV and HR-HPV. To our knowledge, this is the first demonstration of HPV/CMV coinfection of the upper genital tract and CMV infection of the fallopian tubes in patients with EOC. Low amounts of viral DNA copies indicate that CMV and HPV may be present at low activity in EOC tissues. These results suggest that CMV exists in ovarian and fallopian tube cells in a latent phase and could be reactivated under the influence of the inflammatory tumor microenvironment. Extremely low amounts of viral DNA copies and increased levels of specific IgM antibodies found in the majority of patients confirmed our hypothesis. CMV is suspected to act as an oncomodulator that may infect cancer cells and modulate their malignant properties in a way not involving direct transformation$^{36,38}$. Moreover, CMV infection elicits biological responses that are similar to those in chronic inflammation, leukocyte dysfunction, and angiogenesis. CMV coinfection may promote HPV-induced transformation and cause a more rapid development of cancer. Hence, we propose that coinfection with HR-HPV and CMV may be a risk factor for EOC development.

HPV is a carcinogenic virus and a major cause of cervical, anal, penile, and oropharyngeal cancer. A meta-analysis revealed an association between HPV infection and ovarian cancer, as the virus was detected in 17.5% of cases$^{45}$. A geographical discrepancy in HPV prevalence in EOC tissue was found. HPV was detected in 15.5–17.0% of OC patients in North America, 4.0–18.5% in Europe, and 31.4–45.6% in Asia$^{35,33,39,47,49}$. HPV does not play an important role in Western European and North American populations$^{48}$. Although more than 200 different HPV types have been characterized, HPV types 6, 11, 16, 116 and 16 are the most clinically relevant. HPV types 6 and 11 account for approximately 100% of genital wart cases, while 20–50% of lesions also contain coinfections with HR-HPV types$^{46}$. Generally, HPV16, 18, 6, 33, and 45 genotypes were found in ovarian cancer. This study confirmed the common presence of HPV16 in 70% of EOC samples, including ovarian serous carcinomas. HPV16 was the most common genotype followed by HPV18 in other studies, although HPV18 was also identified$^{35,33,40,51,52}$. HPV16 and/or HPV18 were detected not only in OC tissue, but also in fallopian tubes$^{45}$.

HPV is assembled in the superficial layers and replicates without releasing virions into the bloodstream, and thus there is minimal immune recognition by the host. HPV reaches the ovarian epithelium and can be integrated into the genome of EOC cells$^{45,48}$. This results in increased expression of viral E6 and E7 oncoproteins that inactivate two cellular tumor suppressor proteins, p53 and Rb, and leads to increased cell proliferation and malignant transformation. LR-HPV E6 and E7 proteins have lower binding affinities for tumor suppressor proteins compared with those of HR-HPV types$^{45,46}$. Both oncoproteins target the cell cycle regulators, causing suppression of cell apoptosis that leads to extension of cell life span and increase in HPV replication$^{46}$. Moreover, continuous expression of E6 and E7 in HPV-positive cancer cells is linked to significant alterations in the amounts of intra-cellular and exosomal miRNAs that are linked to the regulation of cell proliferation, senescence and apoptosis$^{57}$. The present investigation showed positive amplification in approximately 70% of EOC samples of two CMV genes, UL55 encoding envelope gB and US28 that encodes chemokine receptor US28. Sequence analysis revealed that the CMV gB2 and pUS28 A2 genotype was prevalent in EOC cases, which is in agreement with the genotype distribution in infants and adults from Central Poland$^{46,49}$. Our findings are compatible with the results of Radestad et al., who found the expression of CMV immediate-early (IE) protein in 75% cases, while late CMV tegument protein (pp65) in 67% of ovarian cancer cases in the Gotland (Swedish) population$^{45}$. The results by Shannughapriya et al. showed the presence of low amounts of CMV DNA in 50% of tumor tissue samples obtained from women with EOC, while low protein expression was found in the majority of tissue sections, including those from patients with serous EOC$^{55}$. We found that active CMV infection may occur both in EOC tissues and fallopian tubes. Earlier studies have shown that CMV infection of the fallopian tubes may be associated with ectopic pregnancy$^{56}$. It should be noted, that CMV infection was low-grade and was only detected by employing sensitive techniques such as nested PCR.

CMV is a widespread opportunistic pathogen that is carried by 40–100% of the world’s population, depending on age, socioeconomic status, and geographical location$^{51}$. CMV has developed mechanisms that allow it to survive in latent form in an immunocompetent host, while it reactivates during immunosuppression. CMV can spread to the upper genital tract, and infection is usually persistent, latent and asymptomatic. Several studies have identified high frequency of active CMV infection in tumor tissues, including colorectal cancer$^{52,54}$, malignant glioma$^{64}$, prostatic neoplasia and carcinoma$^{56}$, cervix cancer$^{56}$, and EBV-negative Hodgkin’s lymphoma$^{57}$. Recently, CMV DNA and proteins were detected in ovarian cancer, including HGSOC, and in benign cystadenomas$^{25,43,44}$. CMV is not considered to be oncogenic but is rather oncomodulatory in nature, although the mechanisms of its contribution to cancer remain poorly understood$^{46,70}$. CMV is regarded as an oncomodulator because it promotes cell proliferation, and cell-cell progression, vascular disease development, and immune evasion that contribute to the development of autoimmune diseases and inhibit apoptosis$^{65,71}$. CMV infection may thus promote malignant transformation by controlling of the cell cycle and dysregulating of physiological processes. The CMV US28 gene was shown to be a key mediator of virus-induced vascular disease and has been implicated in models of CMV-associated glioblastoma$^{61,72}$. The US28 protein activates NF-κB, which directly transactivates the CMV major IE promoter$^{53}$ and induces caspase-dependent apoptosis in different cell lines$^{54}$. This signaling pathway
probably plays a role in CMV-mediated inflammatory diseases and CMV-mediated oncogenesis. CMV encodes four proteins, IE1, IE2, pp71, and pUL97 that can bind or phosphorylate Rb family proteins and inhibit the cell cycle arrest functions of p53. Moreover, CMV induces a mesenchymal-to-epithelial transition (MET). In contrast, EBV DNA was occasionally detected in EOC tissue (5% of cases), and no association between EOC and EBV antibody levels was found. Taken together, these results indicate that the role of the EBV in ovarian malignancy is probably less important than that of CMV.

The main limitation of this study was the small sample size and the limited availability of some clinical materials; therefore, HPV and CMV positivity might not reflect a true statistical distribution. Further studies using larger patient groups are needed to confirm our findings. Despite a limited number of specimens in this study, our findings may indicate an important role for HPV, CMV, and coinfection with both in the development of ovarian cancer.

In conclusion, HPV is probably responsible for some cases of ovarian cancer, while CMV may act as oncomodulatory virus and may promote disease progression. A detected coinfection of CMV and HPV in ovarian cancer and/or fallopian tube indicates a potential oncogenic interplay between the two viruses. A randomized control trial is needed to clarify whether anti-viral therapy is beneficial to EOC patients with CMV and/or HPV detected in the tumor. The results may provide new insight into the pathogenesis of ovarian cancer and new strategies for the use of antiviral therapy in oncology patients.

Methods

Study design and participants. Between November 2017 and June 2019, 27 women aged 34–85 years with presumed epithelial ovarian cancer were enrolled in the study. The inclusion criterion was referral for surgery to a specialized center on suspicion of EOC. Women were considered ineligible to participate if they met any of the following criteria: synchronous cancer other than EOC and ovarian cancer of non-epithelial origin. Patients underwent cytoreductive surgery at the Department of Surgical and Oncological Gynecology, Medical University of Lodz, or at the Tomaszow Health Center, Poland performed by the same experienced oncological gynecologist. After a midline longitudinal incision of the abdominal wall, meticulous inspection of the peritoneal cavity was performed, and the tumor was excised for intraoperative pathological examination. Samples of both the tumor tissue and distal part of the fallopian tube (including tubal fimbriae) unilateral to the tumor site were obtained and immediately secured for laboratory tests after confirmation of EOC by a pathologist. Then, cytoreductive surgery was performed with the intention to obtain a complete cytoreduction protocol. The control group consisted of 8 patients aged 37–88 years who underwent surgery for uterine fibroids or benign ovarian tumors. Finally, the tissue material consisted of 20 HGSOCs, 7 ovarian cancers of other histologic types, and 4 metastatic ovarian cancers. Because metastatic ovarian cancer is histologically different from primary ovarian cancer, the patients with metastatic tumors were excluded from the study group and incorporated into a distinct group for comparison. The basic tumor characteristics are presented in Table 1. Tumor and blood samples from patients with benign ovarian cystadenoma were included as a control group. All diagnoses were confirmed by gynecological pathologist at the Department of Pathology, either of the Medical University or the Polish Mother’s Health Center Research Institute, Lodz, Poland. All subjects were of European descent, and there were no ethnic differences between the EOC cases and the control group.

The study protocols were approved by the Bioethics Committee of the Medical University of Lodz (RNN/346/17/KE from 21 November 2017). All procedures performed in the studies were in accordance with the Helsinki declaration. All patients provided written informed consent for participation in this study.

Tissue collection and cultures of primary ovarian cancer cells. Tumor and blood samples were obtained from 27 patients with EOC, 4 patients with metastatic cancer, and 8 patients with benign tumors. In addition, fallopian tube tissue samples were obtained from 10 females diagnosed with EOC and 3 women with metastatic cancers. Tumor and fallopian tube tissue samples were collected at the time of surgery in ice-cold Dulbecco’s Phosphate Buffered Saline (DPBS; Sigma-Aldrich Co. Ltd., Ayrshire, UK) and processed within 1 hour. The solid ovarian cancer specimens were washed with ice-cold DPBS to remove contaminating blood and then minced into small pieces (approximately 1–2 mm³). Primary ovarian cancer cells were isolated from solid specimens using the modified method described by Pribyl et al. The tissue pieces were digested with 150 U/mL collagenase (Sigma-Aldrich, St. Louis, MO, USA) for 30 min at 37 °C and then transferred onto a nylon cell strainer (100 µm; VWR International, Radnor, PA) to separate EOC cells. The cultures were maintained at 37 °C in 5% CO₂ for several days. EOC cells form a confluent monolayer after two weeks in culture. The cells were collected by centrifugation and stored at −80 °C until use.

Cell lines and virus strains. MRC-5 (ATCC CCL-171, American Type Culture Collection, Manassas, VA, USA), HeLa (ATCC CCL-2), and Ca Ski (ATCC CRL-1550) cells were cultured in Eagle’s Minimum Essential Medium (EMEM; Sigma-Aldrich) or RPMI-160 (Sigma-Aldrich), respectively, supplemented with 10% inactivated fetal bovine serum (FBS), 2 mM L-glutamine, and 100 µg streptomycin-100 U penicillin at 37 °C in a 5% CO₂ atmosphere until confluent. HeLa cells contain HPV-18 sequences, whereas Ca Ski cells contain an integrated HPV16 genome as well as sequences related to HPV18. The CMV strain AD-169 (ATCC VR-538) was propagated in MRC-5 cell line in EMEM supplemented with 2% inactivated FBS, L-glutamine, and antibiotics.

CMV serology. Serum samples from the patients were assessed for anti-CMV IgG and IgM antibodies with the use of NovaLisa CMV IgM and IgG assays (NovaTec Immundiagnostica GmbH, Dietzenbach, Germany) based on the enzyme-linked immunosorbent assay (ELISA).

DNA extraction. Genomic DNA isolation from tissue specimens and blood was performed using a QIAamp DNA Mini Kit and Blood Mini Kit (Qiagen GmbH, Hilden, Germany) according to the
Detection and assessment of CMV DNA. The CMV DNA was quantified using a qRT-PCR method with the genesig Standard Kit (Primerdesign Ltd.) according to the manufacturer’s instructions. The DNA corresponding to the CMV UL55 gene was quantified using the 7900HT Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). To validate any positive findings, a negative control without template DNA or RNA was included in each run.

The hypervariable fragments of the CMV genes, UL55 and US28, were amplified with DreamTaq DNA polymerase (Thermo Fisher Scientific, Carlsbad, CA, USA) using a nested and heminested PCR method, as described previously58. DNA isolates from MRC-5 cells infected with CMV laboratory strain AD-169 was used as a positive control, and nuclease-free water was used as a negative control. Positive and negative controls were included with each run. All amplifications were carried out in a Veriti 96-Well Thermal Cycler (Applied Biosystems). The amplicons were separated and analyzed using the QIAxcel system (Qiagen). The retention time of the PCR fragments relative to the QX Alignment Marker 15 bp/1 kb fragments was calculated using the BioCalculator software (Qiagen). The PCR product sizes were determined by comparing the retention time with the QX DNA Size Marker 50–800 bp. The PCR products were sequenced using the MiSeq system (Illumina, San Diego, CA, USA).

Detection of other herpesviruses. The human DNA herpesviruses, including Epstein-Barr virus (EBV), and herpes simplex type 1 (HSV-1) were quantified using a qRT-PCR method with the genesig Standard Kits (Primerdesign Ltd.) as described above. The PCR test has been used for detection of EBV DNA in specimens as described previously78.

Detection and assessment of HPV DNA. The HPV16 and HPV18 copy numbers were quantified using a qRT-PCR method with the genesig Standard Kits (Primerdesign Ltd.) as described above. The test amplifies the region that codes HR-HPV E6 oncoprotein. High risk Human Papillomavirus Multiplex screening genesig kit (Primerdesign Ltd.) was used to simultaneously detection of DNA of 14 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). The DNA was quantified using the LightCycler 96 System (Roche Diagnostics GmbH, Mannheim, Germany). AmpliSens HPV16/18-FRT PCR kit was used for qualitative and quantitative detection and differentiation of HPV types 16 and 18 DNA using real-time hybridization-fluorescence detection of amplified products (InterLabService Ltd., Moscow, Russian Federation). The HPV DNA was quantified using the 7900HT Fast Real-Time PCR system (Applied Biosystems). The uniplex PCR tests with HPV-type specific primers for E6 gene were used for detection of the HPV6, 16, 18, and 45 types79. The amplified products were the following: 291 bp (HPV6), 274 bp (HPV16), 224 bp (HPV18), and 282 bp (HPV45). PCR was performed in a Veriti 96-Well Thermal Cycler (Applied Biosystems). The conditions for amplification with all primers sets were 95 °C for 5 min, 35 cycles at 95 °C for 30 sec, 60 °C for 30 sec, and 72 °C for 60 sec, and a final 5 min extension step. Each PCR was performed in a volume of 50 μl as follows: 0.5 μg template DNA, 5 μl 10 × DreamTaq Buffer (20 mM Tris-HCl, pH 8.0; 1 mM DTT; 0.1 mM EDTA, 100 mM KCl, 0.5% Nonidet P40, 0.5% Tween 20, 50% glycerol), 5 μl 2.5 mM dNTP, 0.5 μl gene-specific primers (100 pmol/μl of each), 0.25 μl DreamTaq polymerase (5 U/μl, Fermentas, Glen Burnie, MD, USA), and nuclease-free water. DNA isolates from Ca Ski and HeLa cells infected with HPV16 and HPV18, respectively, were used as a positive control, and nuclease-free water was used as a negative control. Positive and negative controls were included with each run. The amplicons were separated using the QIAxcel DNA Screening Kit (Qiagen). The results were validated by direct sequencing of selected PCR products using the 96-capillary 3730xl DNA Analyzer (Applied Biosystems) to confirm the detected genotypes.

Statistical analysis. GraphPad Prism 5.00 software (GraphPad Software, San Diego, CA, USA) was used for all analyses. Differences between groups were examined using the Fisher’s exact probability test according to the characteristics of data distribution. Logistic regression was used to calculate the ORs and their corresponding 95% CIs by comparing the case group to the control group. A P-value less than 0.05 was considered statistically significant. The number of samples (n) and the P-values of significant differences are given in tables.
51. Yang, H. J. et al. Comparison of human papillomavirus DNA levels in gynecological cancers: implication for cancer development. *Tumour Biol.* **24**, 310–316 (2003).

52. Zimna, K., Poręba, E., Kędzia, W., Gołdzińska-Jóźefiak, A. & Kędzia, H. Human papillomavirus (HPV) in upper genital tract carcinomas of women. *Eur. J. Gynaec. Oncol.* **18**, 415–417 (1997).

53. Bílik, O. O., Pande, N. T., Pejovic, T. & Buchinska, L. G. The frequency of human papilloma virus types 16, 18 in upper genital tract of women at high risk of developing ovarian cancer. *Exp. Oncol.* **36**, 121–124 (2014).

54. Münger, K. et al. Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. *J. Virol.* **65**, 3943–3948 (1991).

55. Roman, A. & Münger, K. The papillomavirus E7 proteins. *Virology.* **445**, 138–168 (2013).

56. Bordignon, V. et al. How Human Papillomavirus Replication and Immune Evasion Strategies Take Advantage of the Host DNA Damage Repair Machinery. *Viruses.* **9** (2017).

57. Homegger, A. et al. Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncoprotein expression in HPV-positive tumor cells. *PLoS Pathog.* **11**, e1004712 (2015).

58. Paradowski, E. et al. Human cytomegalovirus UL155, UL144, and US28 genotype distribution in infants infected congenitally or postnatally. *J. Med. Virol.* **87**, 1737–1748 (2015).

59. Paradowski, E. et al. Distribution of UL144, US28 and UL155 genotypes in Polish newborns with congenital cytomegalovirus infections. *Eur. J. Clin. Microbiol. Infect. Dis.* **31**, 1335–1345 (2012).

60. Ashki, A. M. Aberrant expression of interleukin-6 and its receptor in Fallopian tubes bearing an ectopic pregnancy with and without tubal cytomegalovirus infection. *Virodisease.* **27**, 340–350 (2016).

61. Cannon, M. J., Schmid, D. S. & Hyde, T. B. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. *Rev. Med. Virol.* **20**, 202–213 (2010).

62. Harkins, L. et al. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. *Lancet.* **360**, 1557–1563 (2002).

63. Chen, H. P. et al. Human cytomegalovirus preferentially infects the neoplastic epithelium of colorectal cancer: a quantitative and histological analysis. *J. Clin. Virol.* **54**, 240–244 (2012).

64. Cobb, C. S. et al. Human cytomegalovirus infection and expression in human malignant glioma. *Cancer Res.* **62**, 3347–3350 (2002).

65. Sanford, E. J., Geder, L., Laychock, A., Rohner, T. J. Jr. & Rapp, F. Evidence for the association of cytomegalovirus with carcinoma of the prostate. *J. Virol.* **118**, 789–792 (1997).

66. Pasca, A., Kummerlander, L., Peitsk, B. & Pali, K. Herpesvirus antibodies and antigens in patients with cervical anaplasia and in controls. *J. Natl. Cancer Inst.* **55**, 775–781 (1975).

67. Huang, G. et al. Human cytomegalovirus in neoplastic cells of Epstein-Barr virus negative Hodgkin’s disease. *Int. J. Oncol.* **21**, 31–36 (2002).

68. Cinatl, J. et al. Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. *Virology.* **505**, 130–138 (2017).

69. Soderberg-Naucler, C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? *J. Intern. Med.* **259**, 219–246 (2006).

70. Vomasske, J., Nelson, J. A. & Streblow, D. N. Human Cytomegalovirus US28: A Functionally Selective Chemokine Binding Receptor. *Infect. Disord. Drug Targets.* **9**, 548–556 (2009).

71. Caposio, P., Orloff, S. L. & Streblow, D. N. The role of cytomegalovirus in angiogenesis. *Viruses Res.* **103**, 13068–13073 (2006).

72. Boomer, J. M., The, T. H., de Leij, L. F. & Harmsen, M. C. The human cytomegalovirus-encoded receptor US28 increases the activity of the major immediate-early promoter/enhancer. *Viruses Res.* **116**, 196–200 (2006).

73. Yoon, H. et al. Unusually high frequency of a 69-bp deletion within the carboxy terminus of the LMP-1 oncogene of Epstein-Barr virus in Burkitt’s lymphoma of Turkish children. *Leukemia.* **20**, 1796–1805 (1998).

74. Okodo, M., Okayama, K., Teruya, K. & Sasagawa, T. Uniplex E6/E7 PCR method detecting E6 or E7 genes in 39 human papillomavirus types. *J. Med. Virol.* **90**, 981–988 (2018).

Acknowledgements
This work was supported by the Statutory Fund of the Institute of Medical Biology of the Polish Academy of Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study. We thank Dr. Wojciech Kocemba from the Department of Gynecology and Obstetrics, Tomaszow Health Center, Tomaszow Mazowiecki, Poland, for providing samples from patients.

Author contributions
J.R.W. and E.P. conceptualized and supervised the study. E.P. drafted the manuscript. A.J. and M.S. performed experiments and analyzed the data. Material from patients was organized by J.R.W. and M.W. Clinical information was prepared by J.R.W. Critical manuscript revisions were done by J.R.W., A.J., M.W. and M.S.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to E.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
